PLEASANTON, Calif., Dec. 5, 2023
/PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that
the Evie Ring, the smart ring designed specifically for women's
health, has received a 2024 CES Innovation Honoree Award in the
wearables category.
The Evie Ring is a valuable new tool for women seeking to take
control of their health. Its innovative form factor designed for
women's fingers, focus on helping women track and analyze their
health and fitness, and emphasis on big-picture data interpretation
rather than individual activity scores sets Evie apart from other
wearables. It has a fresh approach to tracking and displaying key
health and wellness metrics such as menstrual cycles, sleep stages,
and blood oxygen saturation (SpO2) and enables the
logging of information, including menstrual symptoms, mood,
and workouts through the emotionally intelligent Evie App to provide personalized insights that
empower women with actionable data to help them make informed
health decisions.
Movano Health's commitment to offering accurate health
data is demonstrated by its recent FDA application for
SpO2 and heart rate for a ring medical device. The
submission is a testament to the company's dedication to delivering
health tools that women can trust.
"Earning the CES Innovation Award is a momentous achievement for
us and reinforces the importance of our mission," said John Mastrototaro, CEO of Movano Health. "As
highlighted by the increasing emergence of women's health
initiatives such as the one recently announced by the White House,
women have traditionally been underserved in the healthcare market
and there's a shifting focus towards closing this gap. With Evie,
we aim to provide women with more accessible and actionable health
data to help them live healthier lives."
Movano Health will showcase the Evie Ring at CES Unveiled on
January 7, 2024. During CES, Movano
Health will also be demonstrating the breakthrough results of its
most recent blood pressure clinical trial in which its cuffless
prototype and proprietary 4 x 6.7mm System-on-a-Chip demonstrated a
level of accuracy within the standards recognized by the FDA for
blood pressure monitoring devices, a major step forward in its
plans to commercialize a cuffless blood pressure
wearable.
Furthermore, Movano Health is making headway in its non-invasive
glucose monitoring initiative. The Company's patented radio
frequency-enabled technology provides meaningful advantages over
traditional optical sensors with superior accuracy and reliability,
which is agnostic to skin tone.
The Evie Ring is now available for $269 and no subscription fees exclusively at
https://eviering.com/.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is
developing a suite of purpose-driven healthcare solutions to bring
medical-grade, high-quality data to the forefront of consumer
health devices. Featuring modern form factors, Movano Health's
devices capture a comprehensive picture of a person's vital health
information and uniquely translate the data into personalized and
intelligent insights that empower consumers to live healthier and
more balanced lives. Movano Health's end-to-end solutions will soon
enable consumers and their healthcare professionals to utilize
daily medical-grade data as a tool to proactively monitor and
manage health outcomes. For more information on Movano Health,
visit https://movanohealth.com/.
Forward Looking Statements
This press release contains forward-looking statements concerning
our expectations, anticipations, intentions, beliefs, or strategies
regarding the future. These forward-looking statements are based on
assumptions that we have made as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions, and events to differ materially from
those anticipated. Therefore, you should not place undue reliance
on forward-looking statements. Examples of forward-looking
statements include, among others, statements we make regarding
plans with respect to commercial launch of the Evie Ring,
anticipated FDA clearance for the Evie Ring and other products in
development, expected future operating results; product development
and features, product releases, clinical trial, and regulatory
initiatives; our strategies, positioning and expectations for
future events or performance. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements are set forth in our most recent Annual
Report on Form 10-K and any subsequent Quarterly Reports on Form
10-Q, and in our other reports filed with the Securities and
Exchange Commission, including under the caption "Risk
Factors." Any forward-looking statement in this release
speaks only as of the date of this release. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/movano-healths-women-first-wearable-the-evie-ring-receives-2024-ces-innovation-award-302005464.html
SOURCE Movano
